Medicare Data (2025): Once-weekly GLP-1 RAs (especially semaglutide) showed superior MACE reduction compared to SGLT2 inhibitors in Medicare beneficiaries with atherosclerotic cardiovascular disease (ASCVD)
Townsend, [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
The broader health impacts of GLP-1s are just beginning to be felt, showing incredible promise in improving metabolic health and even treating addiction
Filion KB, Joseph L, Boivin JF, Suissa S, Brophy JM
However, the exact role of O-GlcNAc in specific injuries needs further investigation, which may contribute to the development of novel therapeutic strategies